Nuzenio

Ii Study

Ii Study news intelligence with latest source-attributed stories, timeline, related explainers, connected entities, source diversity, and FAQ.

topic 10 latest news signals 7 publisher sources 100/100 entity strength

Latest news

Impressive top-line Phase II results for AbCellera’s ABCL635 - The Pharma LetterThe Pharma Letter · Mon, 10 Aug 2026 15:11:15 GMTFirst patient dosed with AK146D1 in Akeso’s Phase II study - Clinical Trials ArenaClinical Trials Arena · Mon, 10 Aug 2026 13:34:39 GMTAbCellera’s ABCL-635 Cuts Menopause Hot Flashes 83% in Phase II Trial - Yahoo FinanceYahoo Finance · Mon, 10 Aug 2026 13:03:44 GMTGenfleet becomes first to test oral KRAS G12D inhibitor in Phase III for NSCLC - AllSciAllSci · Mon, 10 Aug 2026 10:33:20 GMTAkeso Advances IO2.0 + ADC2.0 Strategy: First Patient Dosed in Phase II Study of TROP2/Nectin-4 Bispecific ADC (AK146D1) Combined with Ivonescimab in Breast Cancer - The Manila TimesThe Manila Times · Mon, 10 Aug 2026 04:31:46 GMTDNLI Q2 Loss Narrows, Avlayah Sales Drive Strong Launch Momentum - TradingViewTradingView · Fri, 07 Aug 2026 18:31:00 GMTMediar partners with Ono Pharma on fibro-inflammatory discovery - AllSciAllSci · Thu, 06 Aug 2026 16:25:44 GMTBezisterim meets motor and non-motor endpoints in phase II early Parkinson's trial. - AllSciAllSci · Thu, 06 Aug 2026 16:12:09 GMT

Timeline

Mon, 10 Aug 2026 15:11:15 GMTImpressive top-line Phase II results for AbCellera’s ABCL635 - The Pharma Letter
Mon, 10 Aug 2026 13:34:39 GMTFirst patient dosed with AK146D1 in Akeso’s Phase II study - Clinical Trials Arena
Mon, 10 Aug 2026 13:03:44 GMTAbCellera’s ABCL-635 Cuts Menopause Hot Flashes 83% in Phase II Trial - Yahoo Finance
Mon, 10 Aug 2026 10:33:20 GMTGenfleet becomes first to test oral KRAS G12D inhibitor in Phase III for NSCLC - AllSci
Mon, 10 Aug 2026 04:31:46 GMTAkeso Advances IO2.0 + ADC2.0 Strategy: First Patient Dosed in Phase II Study of TROP2/Nectin-4 Bispecific ADC (AK146D1) Combined with Ivonescimab in Breast Cancer - The Manila Times
Fri, 07 Aug 2026 18:31:00 GMTDNLI Q2 Loss Narrows, Avlayah Sales Drive Strong Launch Momentum - TradingView

FAQ

What does this page track?

Latest RSS headlines, source names, timestamps, related explainers, connected entities, and timeline signals for Ii Study.

Why might this page be noindex?

Nuzenio only indexes entity pages after enough useful source-attributed coverage and source diversity exists.

Where should readers verify facts?

Open the original publisher links from each story for full reporting, quotes, figures, images, corrections, and updates.

Source diversity

7 distinct publisher/source names are currently connected to this entity page.